PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and ...

PEDMARK (sodium thiosulfate injection)PEDMARK is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin ...

PEDMARQSI ® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children ...

(MENAFN- GlobeNewsWire - Nasdaq) ~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ...

TSX:FRX) Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management ...

SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors. PEDMARK® (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric ...

Indications and Usage PEDMARK® (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with ...

For more information on Petrichor, please visit www.petrichorcap.com. PEDMARK (sodium thiosulfate injection)PEDMARK is the first and only U.S. Food and Drug Administration (FDA) approved therapy ...